CACZ885U2301

Research code: CACZ885U2301
Research name: Randomised, double-blind, placebo-controlled phase III research evaluating the efficacy and safety of pembrolizumab in combination with platinum derivative-based two-drug chemotherapy, with or without canakinumab, for the first-line treatment of patients with locally advanced or metastatic non-squamous and squamous non-small cell lung cancer (CANOPY-1).
Indication: lung cancer
Principal researcher: Ewa Chmielowska, MD, PhD